|
Jan 30
|
Sanofi plans share buybacks, signals more deals post Opella sale
|
|
Jan 30
|
Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025
|
|
Jan 29
|
Sanofi: Information concerning the total number of voting rights and shares - December 2024
|